Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Lung Cancer”

1,357 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,357 results

Early research (Phase 1)Looking for participantsNCT06905197
What this trial is testing

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

Who this might be right for
Non Small Cell Lung Cancer
Dizal Pharmaceuticals 140
Testing effectiveness (Phase 2)Study completedNCT00321815
What this trial is testing

Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 43
Large-scale testing (Phase 3)UnknownNCT04500717
What this trial is testing

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation

Who this might be right for
Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 460
Testing effectiveness (Phase 2)Study completedNCT03239340
What this trial is testing

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

Who this might be right for
EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca 154
Not applicableStudy completedNCT04261725
What this trial is testing

Prevalence of EGFR Mutations in epidermoïd Bronchopulmonary Cancers in Réunion Island

Who this might be right for
Squamous Cell Lung Cancer
Centre Hospitalier Universitaire de la Réunion 60
Testing effectiveness (Phase 2)UnknownNCT02951637
What this trial is testing

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Who this might be right for
Lung Adenocarcinoma
Shanghai Chest Hospital 300
Large-scale testing (Phase 3)Not Yet RecruitingNCT06908772
What this trial is testing

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

Who this might be right for
Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
Shanghai JMT-Bio Inc. 390
Testing effectiveness (Phase 2)Looking for participantsNCT04335292
What this trial is testing

Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

Who this might be right for
Non-Small Cell Lung Cancer
Mark Vincent 200
Not applicableLooking for participantsNCT06053099
What this trial is testing

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

Who this might be right for
Non Small Cell Lung CancerEGFR Activating MutationEGFR DEL19+1 more
Intergroupe Francophone de Cancerologie Thoracique 300
Not applicableStudy completedNCT02418234
What this trial is testing

T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure

Who this might be right for
Non-small Cell Lung Cancer Stage IIINon-Small-Cell Lung Cancer Metastatic
First People's Hospital of Hangzhou 314
Early research (Phase 1)Active Not RecruitingNCT03333343
What this trial is testing

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Who this might be right for
EGFR-mutant Non-small Cell Lung Cancer
Novartis Pharmaceuticals 105
Not applicableApproved For MarketingNCT06279728
What this trial is testing

Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients

Who this might be right for
EGFRm Advanced Non-Small Cell Lung CancerEGFRm Metastatic Non-Small Cell Lung Cancer
Daiichi Sankyo
Testing effectiveness (Phase 2)Temporarily pausedNCT02470065
What this trial is testing

Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.

Who this might be right for
Non Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC 38
Testing effectiveness (Phase 2)UnknownNCT03002844
What this trial is testing

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Who this might be right for
Nonsmall Cell Lung CancerEGFR Gene Mutation
Shanghai Pulmonary Hospital, Shanghai, China 50
Large-scale testing (Phase 3)Study completedNCT00981058
What this trial is testing

First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin

Who this might be right for
Non Small Cell Lung Cancer
Eli Lilly and Company 1,093
Testing effectiveness (Phase 2)Looking for participantsNCT07379476
What this trial is testing

Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer (NSCLC)
Chinese University of Hong Kong 64
Not applicableUnknownNCT02852798
What this trial is testing

Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC

Who this might be right for
Nonsquamous Nonsmall Cell Neoplasm of Lung
Jiangsu ShengDiYa Medicine Co., Ltd. 60
Testing effectiveness (Phase 2)Ended earlyNCT02349633
What this trial is testing

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Who this might be right for
Non-Small Cell Lung Cancer
Pfizer 65
Not applicableStudy completedNCT02695849
What this trial is testing

Prevalence of EGFR Mutations in Participants With NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 69
Not applicableStudy completedNCT04207775
What this trial is testing

Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy

Who this might be right for
Locally Advanced or Metastatic NSCLC
AstraZeneca 300
Load More Results